Company: SUPN
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001356576-25-000071
Chunk: 103

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 103
---
 — — — 19,916 19,916 Unrealized gain on marketable securities, net of tax— — — 162 — 162 Balance, June 30, 202455,046,049 55 455,170 (372)502,601 957,454 Share-based compensation expense related to employee stock purchase plan and share-based awards— — 7,674 — — 7,674 Issuance of common stock related to employee stock purchase plan and share-based awards, net of taxes withheld173,224 — 3,075 — — 3,075 Net earnings— — — — 38,497 38,497 Unrealized gain on marketable securities, net of tax— — — 450 — 450 Balance, September 30, 202455,219,273 $55 $465,919 $78 $541,098 $1,007,150 

See accompanying notes.

7

 Supernus Pharmaceuticals, Inc.

Condensed Consolidated Statements of Cash Flows

(in thousands)September 30,20252024(unaudited)Cash flows from operating activitiesNet earnings (loss)$(34,445)$58,537 Adjustments to reconcile net earnings to net cash provided by operating activities:Depreciation and amortization66,547 61,569 Amortization of premium/discount on marketable securities(2,027)2,497 Change in fair value of contingent consideration7,660 (6,466)Realized gains from sales of marketable securities— (9)Share-based compensation expense23,400 20,123 Deferred income tax benefit(13,797)(20,064)Inventory valuation write-down1,228 1,993 Payment of contingent consideration(4,900)— Other noncash adjustments, net7,606 6,288 Changes in operating assets and liabilities:Accounts receivable(5,885)(1,253)Inventories(3,322)12,619 Prepaid expenses and other assets(6,274)(8,542)Accrued product returns and rebates15,754 14,850 Accounts payable and other liabilities(24,075)(14,597)Net cash provided by operating activities27,470 127,545 Cash flows from investing activitiesPurchases of